These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment. Fei M; Jianghua W; Rujuan M; Wei Z; Qian W J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911 [TBL] [Abstract][Full Text] [Related]
8. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403 [TBL] [Abstract][Full Text] [Related]
9. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084 [TBL] [Abstract][Full Text] [Related]
10. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117 [TBL] [Abstract][Full Text] [Related]
11. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition. Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509 [TBL] [Abstract][Full Text] [Related]
13. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967 [TBL] [Abstract][Full Text] [Related]
14. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline. Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M; Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729 [TBL] [Abstract][Full Text] [Related]
15. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377 [TBL] [Abstract][Full Text] [Related]
16. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652 [TBL] [Abstract][Full Text] [Related]
18. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study. Sheng C; Yang K; He B; Du W; Cai Y; Han Y Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860 [TBL] [Abstract][Full Text] [Related]
19. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L; Raimondi I; Jovicich J; Babiloni C; Soricelli A; Lizio R; Galluzzi S; Cavaliere L; Didic M; Schönknecht P; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Bocchio L; Salvatore M; Rossini PM; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Forloni G; Frisoni GB; J Alzheimers Dis; 2019; 69(1):37-48. PubMed ID: 30149449 [TBL] [Abstract][Full Text] [Related]
20. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]